Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies
N. Han, W. Hwang, K. Tzelepis, P. Schmerer, E. Yankova, M. MacMahon, W. Lei, N. M. Katritsis, A. Liu, A. Schuldt, R. Harris, K. Chapman, F. McCaughan, F. Weber, T. Kouzarides
The paper identifies 200 approved drugs that target SARS-CoV-2-induced pathways, with 40 in clinical trials, and classifies them into viral replication and immune response mechanisms.
bioRxiv · Aug 24, 2020Pharmacology & Toxicology